In this video as part of The Motley Fool's "Ask a Fool" series, Fool health-care analyst David Williamson takes a question from a Fool reader, who writes, "What's your Foolish opinion on Organovo (NYSEMKT: ONVO ) ? Buy, sell, or hold?"
David introduces investors to the company, which is working to develop the ability to use 3-D printing technology to create human livers, which would facilitate medical testing for liver toxicity without having to test on actual humans. David also warns that even though this is a potentially disruptive force, it's still so early in the development of its product that there's still a lot of risk for investors here, and he advises keeping this as no more than a tiny percentage of any investment portfolio.
Medical technology is changing so rapidly, how should investors pick winners?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.